Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more
Applied Therapeutics Inc (APLT) - Net Assets
Latest net assets as of September 2025: $-561.00K USD
Based on the latest financial reports, Applied Therapeutics Inc (APLT) has net assets worth $-561.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.37 Million) and total liabilities ($34.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-561.00K |
| % of Total Assets | -1.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | -30.43% |
| 10-Year Change | N/A |
| Growth Volatility | 239.58 |
Applied Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Applied Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Applied Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $57.01 Million | +432.47% |
| 2023-12-31 | $-17.15 Million | -522.21% |
| 2022-12-31 | $4.06 Million | -93.51% |
| 2021-12-31 | $62.54 Million | -23.68% |
| 2020-12-31 | $81.94 Million | +151.29% |
| 2019-12-31 | $32.61 Million | +106.14% |
| 2018-12-31 | $15.82 Million | +499.34% |
| 2017-12-31 | $-3.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Applied Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56947400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $35.00K | 0.06% |
| Other Components | $631.18 Million | 1107.22% |
| Total Equity | $57.01 Million | 100.00% |
Applied Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Applied Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jenkongklai PCL
BK:JPARK
|
$12.34 Million |
|
Wijaya Karya Beton
JK:WTON
|
$12.34 Million |
|
AGAT EJENDOMME NAM. DK 1
F:2TD
|
$12.36 Million |
|
CryoCell International Inc
NYSE MKT:CCEL
|
$12.36 Million |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
$12.34 Million |
|
Tron Inc.
NASDAQ:TRON
|
$12.33 Million |
|
SAGA PURE ASA NK 1
F:SAT
|
$12.33 Million |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
$12.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Applied Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -17,146,000 to 57,006,000, a change of 74,152,000.
- Net loss of 105,624,000 reduced equity.
- New share issuances of 104,748,000 increased equity.
- Other factors increased equity by 75,028,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-105.62 Million | -185.29% |
| Share Issuances | $104.75 Million | +183.75% |
| Other Changes | $75.03 Million | +131.61% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Applied Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.43 | $0.10 | x |
| 2018-12-31 | $1.73 | $0.10 | x |
| 2019-12-31 | $2.54 | $0.10 | x |
| 2020-12-31 | $3.73 | $0.10 | x |
| 2021-12-31 | $2.44 | $0.10 | x |
| 2022-12-31 | $0.11 | $0.10 | x |
| 2023-12-31 | $-0.20 | $0.10 | x |
| 2024-12-31 | $0.41 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Applied Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -185.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23214.07%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.52x
- Recent ROE (-185.29%) is above the historical average (-342.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.89 Million |
| 2018 | -104.44% | 0.00% | 0.00x | 1.28x | $-18.10 Million |
| 2019 | -139.22% | 0.00% | 0.00x | 1.48x | $-48.66 Million |
| 2020 | -113.53% | 0.00% | 0.00x | 1.28x | $-101.22 Million |
| 2021 | -167.28% | 0.00% | 0.00x | 1.44x | $-110.87 Million |
| 2022 | -2031.72% | -774.00% | 0.28x | 9.45x | $-82.91 Million |
| 2023 | 0.00% | -1198.47% | 0.18x | 0.00x | $-118.05 Million |
| 2024 | -185.29% | -23214.07% | 0.01x | 1.52x | $-111.32 Million |
Industry Comparison
This section compares Applied Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Applied Therapeutics Inc (APLT) | $-561.00K | 0.00% | N/A | $12.34 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |